Celldex Therapeutics stock gains as analysts lift expectations

Celldex Therapeutics stock (ISIN US15117B1035) is trading near the upper end of its recent range, with a last quoted level of USD 38.98 on Nasdaq as of mid-September 2026, reflecting renewed analyst optimism on the company’s growth prospects.

Analysts see strong revenue ramp

Analyst consensus data compiled on September 17, 2026 shows that for the current quarter ending September 2026, Celldex Therapeutics is expected to generate average revenue of USD 883,220, while estimates for the next quarter ending December 2026 stand at USD 1.36 million.Yahoo Finance The same overview indicates that analysts project current-year 2026 revenue of USD 2.03 million, rising sharply to USD 12.73 million in 2027, highlighting expectations for a substantial scaling of the company’s pipeline into potential commercial revenues.Yahoo Finance

In terms of growth, the same analyst dataset compares estimated sales for 2026 and 2027 with prior-year levels and shows that projected next-quarter revenue of USD 1.36 million implies an increase of more than tenfold versus the year-ago quarterly sales figure of approximately USD 121,000, while the move from 2026 to 2027 represents an expected revenue growth rate of 526.65 percent.Yahoo Finance For investors, these numbers illustrate how much of the current valuation rests on future expansion rather than on today’s still modest reported sales base.

Recent quarterly loss frames risk profile

While the top line is expected to accelerate, Celldex remains a loss-making biotechnology company, a key risk factor that investors must weigh against the growth story. According to a recent performance snapshot referencing second-quarter 2026, the company reported revenue of only USD 22,000 in that period, coupled with a net loss of about USD 73.5 million.Yahoo Finance This translates into an extremely negative profit margin, underscoring that Celldex is still firmly in the investment and development phase.

The same data set shows that earnings per share for the second quarter of fiscal 2026 came in at a GAAP loss of USD 0.94, better than the consensus estimate of a USD 1.06 loss but still extending a series of negative EPS prints over recent quarters.Yahoo Finance For comparison, historical figures in the same earnings history overview show prior quarterly EPS losses of USD 1.01, USD 1.22 and USD 1.18, indicating that although the latest USD 0.94 loss is slightly less severe, Celldex still needs to close a significant gap before approaching break-even.

Analyst ratings and price targets support valuation

Beyond the raw numbers, analyst recommendations provide further context for Celldex Therapeutics stock. A recent note highlighted that Morgan Stanley increased its price target on Celldex from USD 46.00 to USD 50.00 and reiterated an overweight rating in a research update dated September 10, 2026, signaling confidence in the company’s medium-term prospects.MarketBeat The same overview reports that, based on compiled research, Celldex currently carries an average rating of Moderate Buy with a consensus price target of USD 56.42, considerably above the recent Nasdaq price in the high USD 30s.MarketBeat

That gap between the consensus price target of around USD 56 and the recent trading level near USD 38.98 suggests that, in the view of covering analysts, there is significant upside potential if Celldex can deliver on its forecast revenue ramp and successfully advance its pipeline assets through later-stage clinical trials and toward potential regulatory approvals.MarketBeat At the same time, the persistent operating losses and dependence on future milestones mean that the stock’s risk profile remains elevated compared with more mature pharmaceutical peers.

Stock trades near recent highs

In the latest trading snapshot, Celldex Therapeutics stock opened on Nasdaq at USD 38.98, with the quote cited in a market report as of September 18, 2026 and referring to the prior session’s opening level for CLDX.MarketBeat Market data around mid-September 2026 also point to a market capitalization in the low billion-dollar range and a trading pattern where the current price is closer to the upper half of the 52-week interval, indicating that the stock has already priced in part of the expected future growth.

Closing price context for investors

As of the most recent completed Nasdaq session referenced on September 18, 2026, Celldex Therapeutics stock closed around USD 38.98 in United States dollars, positioning the shares below the average analyst price target but above earlier levels seen when revenue expectations were lower. For investors, the combination of a still loss-making business, a projected multi-fold increase in revenue between 2026 and 2027, and supportive analyst price targets defines the current balance between opportunity and risk in CLDX.

More news and analyses on Celldex Therapeutics stock